Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022
Share
Sunmax Biotechnology Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 364.76 million compared to TWD 252.59 million a year ago. Revenue was TWD 363.59 million compared to TWD 252.39 million a year ago. Net income was TWD 137.32 million compared to TWD 41.62 million a year ago. Basic earnings per share from continuing operations was TWD 2.52 compared to TWD 0.76 a year ago. Diluted earnings per share from continuing operations was TWD 2.52 compared to TWD 0.76 a year ago. Basic earnings per share was TWD 2.52 compared to TWD 0.76 a year ago. Diluted earnings per share was TWD 2.52 compared to TWD 0.76 a year ago.
For the nine months, sales was TWD 1,012.26 million compared to TWD 754.38 million a year ago. Revenue was TWD 1,010.31 million compared to TWD 754.18 million a year ago. Net income was TWD 409.28 million compared to TWD 149.07 million a year ago. Basic earnings per share from continuing operations was TWD 7.51 compared to TWD 2.74 a year ago. Diluted earnings per share from continuing operations was TWD 7.51 compared to TWD 2.73 a year ago. Basic earnings per share was TWD 7.51 compared to TWD 2.74 a year ago. Diluted earnings per share was TWD 7.51 compared to TWD 2.73 a year ago.
SunMax Biotechnology Co., Ltd. is a Taiwan-based company principally engaged in research, development, production and distribution of collagen implants and related products. The Company's major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, as well as medical collagen application equipment. Its products are applied in medical and beauty care industrials. The Company distributes its products principally in Taiwan, Mainland China and other regions.